Abiopharma

Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference

RadNet Names Four Leaders to Expanded Executive Roles

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

Labeling changes approved for RISING. Active ingredient: MECLIZINE HYDROCHLORIDE. Decision date: 01/06/2026

Mersana Therapeutics (MRSN) was removed from the list of traded instruments on NASDAQ exchange

CureVac (CVAC) was removed from the list of traded instruments on NASDAQ exchange

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Interested Person Transaction: RENEWAL OF TENANCY AGREEMENT WITH CHEE AND HEAH SURGICAL ASSOCIATES PTE. LTD.

NASDAQ symbol attribute type Security_Name was changed. Previous value: CureVac N.V. - Ordinary Shares. New value: CureVac N.V. - Ordinary Shares.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: CureVac N.V. - Ordinary Shares.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Mersana Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Mersana Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: CureVac N.V. - Ordinary Shares.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Mersana Therapeutics, Inc. - Common Stock. New value: Mersana Therapeutics, Inc. - Common Stock.

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B